WO2024023572A1 - Sang enrichi en iode moléculaire, son procédé de préparation et ses utilisations - Google Patents

Sang enrichi en iode moléculaire, son procédé de préparation et ses utilisations Download PDF

Info

Publication number
WO2024023572A1
WO2024023572A1 PCT/IB2022/057066 IB2022057066W WO2024023572A1 WO 2024023572 A1 WO2024023572 A1 WO 2024023572A1 IB 2022057066 W IB2022057066 W IB 2022057066W WO 2024023572 A1 WO2024023572 A1 WO 2024023572A1
Authority
WO
WIPO (PCT)
Prior art keywords
blood
molecular iodine
enriched
iodine
treatment
Prior art date
Application number
PCT/IB2022/057066
Other languages
English (en)
Inventor
Pietrina Romano
Original Assignee
Romano Laboratory Srls
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Romano Laboratory Srls filed Critical Romano Laboratory Srls
Priority to PCT/IB2022/057066 priority Critical patent/WO2024023572A1/fr
Publication of WO2024023572A1 publication Critical patent/WO2024023572A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Definitions

  • the present invention relates to hemotherapy, more particularly to a molecular iodine- enriched blood and its use in the treatment and prevention of several diseases, including cancer.
  • the invention also relates to process for the preparation of said molecular iodine- enriched blood.
  • molecular iodine Besides its effects as part of thyroid hormones, molecular iodine (I2) exerts multiple and complex actions on organs that capture it.
  • This chemical form of iodine is internalized by a facilitated diffusion system that is evolutionary conserved, and its effects appear to be mediated by a variety of mechanisms and pathways.
  • As an oxidized component it directly neutralizes free radicals, induces the expression of type II antioxidant enzymes, or inactivates proinflammatory pathways.
  • I2 In neoplastic cells, I2 generates iodolipids that have an antineoplastic effect with mitochondrial and nuclear mechanisms that include the activation of apoptotic pathways and the inhibition of markers related to stem cell maintenance, chemoresistance, and survival.
  • I2 has been postulated as an immune modulator that, depending on the cellular metabolic context, can function as an inhibitor or activator of immune responses.
  • Iodine can be found in nature and in many states of oxidation either organic and inorganic.
  • Molecular iodine I2 being an apolar molecule, is taken up by a facilitated diffusion system, independent of the sodium iodine symporter (NIS) or Pendrin (PEN), necessary, instead, for the absorption of iodides and all other iodine-based ionic compounds and the oxidized iodine form I2 is organified in the absence of peroxidases.
  • NIS sodium iodine symporter
  • PEN Pendrin
  • I2 diffuses through all cell membranes, including mitochondrial and nuclear membranes, where iodine, by binding to histones, is able to modulate the expression of particular genes, directly and indirectly exerting epigenetic effects.
  • I2 acts as a scavenger of a reactive oxygen species (ROS) like hydroxyl radicals (OH) or superoxide anions (O2) generating neutral components hypoiodous acid (HIO) or hydroiodic acid (HI).
  • ROS reactive oxygen species
  • I2 in combination with arachidonic acid (AA), and generating the iodolipid 6-iodolactone (6-IL), inhibits the activity of proinflammatory enzymes like Nitric Oxide Synthase (NOS) and Cyclooxygenase type 2 (Cox2).
  • ROS reactive oxygen species
  • NOS Nitric Oxide Synthase
  • Cox2 Cyclooxygenase type 2
  • molecular iodine has an antiproliferative and apoptotic effect either in vivo and in vitro.
  • molecular iodine supplementation exerts a suppressive effect on the development and size of both benign and cancerous neoplasias.
  • I2 but not iodide (T) supplementation alleviates human mastalgia and exerts a potent antineoplasic effect on pharmaco-induced mammary tumoral progression in rats.
  • T iodide
  • ROS reactive nitrogen species
  • hypoxia is a characteristic feature of locally advanced tumors resulting from an imbalance between oxygen (O2) supply and consumption.
  • Major causative factors of tumor hypoxia are abnormal structure and function of the microvessels supplying the tumor, increased diffusion distances between the nutritive blood vessels and the tumor cells, and reduced O2 transport capacity of the blood due to the presence of disease- or treatment-related anemia. So, a common feature of most tumors is glycosylation changes and a low level of oxygen, which severity depends on tumor types, though it is generally accepted that oxygen levels in tumor tissues is poorer than in the respective normal tissues and on average it is between l%-2% O2 or even below.
  • Metabolic disorders such as oxidation, dehydration and persistent hypoxia in cancer patients, determine and maintain multiple morphological and volumetric asymmetries of erythrocytes (loss of membrane potential, Fe oxidation of hemoproteins with serious consequences including Heinz Body formation).
  • composition of the invention in therapy, especially, but not limited to, in cancer therapy.
  • Figures 1 to 4 show peripheral blood of a cancer patient before (B) and after (A) blood purification (optical microscope).
  • Figures 5 to 7 show peripheral blood of a cancer patient (SEM - Scan Electron Microscopy).
  • Figure 8 shows peripheral blood of a cancer patient treated according to the invention.
  • a blood enriched with molecular iodine is a subject-matter of the invention a blood enriched with molecular iodine.
  • Blood enriched with molecular iodine must be well oxygenated, where the expression "well-oxygenated” is defined below as a function of partial oxygen pressure.
  • a purified bloodenriched with molecular iodine characterized in that said blood is subjected to a purification treatment, before the addition of said molecular iodine.
  • purified blood herein means that said blood has been subjected to a purification treatment so that it has been re-oxygenated.
  • a purification treatment may be any suitable one, such as for example, GAET (Great Auto Hemotransfusion), EV- LLLT (EndoVenous -Low Level Laser Therapy), Dialysis and Plasmapheresis, which are well known in the art.
  • the purification can be made ex vivo, i.e. samples of venous blood are purified before the treatment with iodine.
  • the purification may be partial or total, (according to the method used).
  • well-oxygenated blood enriched with molecular iodine “molecular iodine-enriched purified blood” are synonyms and herein indicate a blood, as herein defined, which has been added with molecular iodine.
  • the blood enriched with molecular iodine of the invention is a well oxygenated blood, where the expression "well oxygenated” indicates that a venous blood having a partial pressure of oxygen, also known as pCL, ranging from 35 to 40 mmHg, preferably about 40 mmHg.
  • partial pressure of oxygen is a measurement of oxygen pressure in blood. If the blood sample is not well oxygenated, that is, it does not have the partial pressure of oxygen, must then be subjected to purification for become a "purified blood” suitable for use according to the invention.
  • purified blood therefore indicates a venous blood with a partial oxygen pressure ranging from 35 to 40 mmHg, preferably about 40 mmHg.
  • concentration of molecular iodine in said molecular iodine-enriched purified blood ranges from 40 to 92 pg/L, more preferably 70 pg/L.
  • the blood sample that is to be enriched with molecular iodine has a partial oxygen pressure ranging from 35 to 40 mmHg, preferably about 40 mmHg, then it can be directly enriched by introducing molecular iodine, as will be described below.
  • the blood sample that must be enriched with iodine has a partial oxygen pressure of less than 35 mmHg, then said sample shall be subjected to a purification treatment as described here.
  • the purification of the blood has the aim of re-oxygenating, correcting the morphological and functional changes in erythrocytes, contrasting rouleaux formation, which are primarily caused by the oxidative and nitrosative stress of cancer cells.
  • molecular iodine (I2) has multiple effects, either genetic and metabolic, directly on blood and on the apoptosis of cancer cells, through an independent Caspase pathway; molecular Iodine also acts on the activation of the nuclear receptor PPARy (Peroxisome Proliferator-Activated Receptor gamma), mediated by 6-Iodiolactone, on the activation of the immune system and on histones and therefore on epigenetic control of several genes.
  • nuclear receptor PPARy Peroxisome Proliferator-Activated Receptor gamma
  • Iodine (and not iodide or other iodine ionic derivatives) crossing all membranes by facilitated diffusion, enters cells, organelles, mainly mitochondria, and nucleus. Iodine plays an essential role in the mitochondria in which it activates apoptosis of cancer cells, activates the immune system, regulates nuclear receptors and the direct and indirect expression of several genes.
  • purification of blood allows blood to re-oxygenate and re-oxygenate tissues, reducing hypoxia, which, as is known, is a essential factor to maintain an environment conducive to cancer development of cancer and other numerous degenerative and non-degenerative pathologies; the purification also restores the membrane potential of red blood cells, reduce carbohydrates, especially L-Fucose that leads mitochondria to anaerobic respiration, rebalances receptors including EGFR (Epidermal Growth Factor Receptor) and NOTCH that activate mitosis, all contributing to the goal of detoxifying the body from the tumor siege.
  • EGFR Epidermatitise
  • NOTCH that activate mitosis
  • molecular iodine treatment reactivates apoptosis of cancer cells, regulates the immune system, reactivates aerobic respiration together with oxygen, reactivates cell differentiation, reactivates receptors, including the PPARy nuclear receptor and epigenetically regulates the expression of numerous genes; also, molecular iodine does not have the same effects as iodide on heart and thyroid, is not absorbed differently as a function of the expression of NIS and Pendrin Receptors, but absorbed by diffusion facilitated by all biological membranes: cellular, mitochondrial and nuclear; finally molecular iodine crosses the blood-brain barrier and the action of molecular iodine does not depend on enzymatic bioavailability.
  • the blood purification of patients cancer also serves to eliminate substances interfering with iodine.
  • L-Fucose a methyl pentose that is present in higher concentrations in the blood of cancer patients, is able to react with iodine and it is therefore useful to reduce concentrations in the blood through purification, to promote the bioavailability of the iodine.
  • the purification then is useful to decrease the concentration so that the iodine infusion reaches the tissues through the blood.
  • the blood enriched with molecular iodine according to the invention has a partial oxygen pressure ranging from 30 to 40 mmHg and is free or substantially free of compounds that interact with iodine, such as L-Fucose. Hemotherapy could be used to achieve and/or maintain response to conventional treatments.
  • the treatment is economical and painless and does not affect the quality of life of the cancer patient, which already compromised by the disease and by any cancer treatments previously administered.
  • red blood cells can be the stacking of red blood cells to "rouleaux” and the alterations of their morphology in cancer patient’s blood to aggravate hypoxia; indeed, the morphological, functional and metabolic changes of the red blood cells compromise their potential for the extraction and transport of oxygen in the blood.
  • iodine reaches cancer cells: -inducing apoptosis in cancer cells; -activating: a proper differentiation, the immune system and several receptors including PPARy.
  • PPAR receptors play a pivotal role in restoring metabolic balance in healthy tissues, activating differentiation, actively counteracting inflammation and invasion of cancer cells in the body.
  • Mitochondria also play a fundamental role in the induction of apoptosis and the activation of aerobic respiration against anaerobic glycolysis typical of cancer cells.
  • a process for the preparation of molecular iodine-enriched blood which comprises the following steps: a. optionally subjecting a sample of blood to a purification treatment, to obtain a reoxygenated blood, wherein purified blood is as above defined; b. adding a water solution of molecular iodine to the purified blood sample of step a., preferably to a concentration of 40 to 92 pg/L.
  • said purification treatment is preferably selected from: GAET, EV- LLLT, Dialysis and Plasmapheresis, although any suitable purification treatment, more suitable for the patient’s clinical condition, can be used.
  • the water solution of molecular iodine of step b. has a concentration of molecular iodine from 0.1 mM to 1 mM, more preferably 0.5 to 1 mM, most preferably about 1 mM.
  • a water solution having the desired concentration of molecular iodine is prepared and added to the purified blood of step a..
  • a ImM h water solution may be prepared according to the following redox
  • stabilized solutions of molecular iodine can be prepared and used.
  • the molecular iodine-enriched blood of the invention is to be administered by infusion in a subject in need thereof, according to the known methods of hemotherapy.
  • the infused amount is initially lower than the RDA (Recommended Dietary Allowance - RDA- for Iodine related to age - ICCIDD) and subsequently increased up to the RDA.
  • RDA for iodine are the following:
  • the blood may be either a compatible donor blood, or a previously drawn blood of the same cancer patient.
  • the molecular iodine-enriched blood of the invention for its use in therapy especially for use in the treatment and/or prevention of cancer, and/or in the treatment and/or prevention of metastases represents another subject-matter of the invention.
  • the blood of the invention is useful for the treatment of any cancer or metastasis, either solid or liquid.
  • the molecular iodine-enriched blood of the invention represents an effective and safe treatment that does not interfere with the heart and/or thyroid gland and is a cost-effective clinical treatment.
  • said treatment is repeated, for instance 1 to 6 months apart, preferably 2-5 months apart, more preferably 2 months apart, after the suitable clinical controls, such as routine post diagnosis checks, as TAC PET, RMN, blood test and others.
  • the molecular iodine-enriched blood of the invention is therefore suitable to be used as an effective solid and liquid cancer therapy. Therapy can be used without age or gender limits.
  • the molecular iodine-enriched blood may be also used in combination with chemotherapies, or other cancer therapies, such as radiotherapy.
  • the invention relates to the molecular iodine- enriched purified blood of the invention in combination with further drugs, chemotherapies and/or other cancer therapies, for use in the treatment and/or prevention of cancer and metastasis.
  • the invention relates to a method for the treatment and/or prevention of cancer and metastasis which comprises administering to a subject in need thereof the molecular iodine-enriched blood of the invention.
  • the invention relates to a method for the treatment and/or prevention of cancer and metastasis, which comprises administering to a subject in need thereof a molecular iodine-enriched blood of the invention in combination with other drugs and/or cancer therapies.
  • the invention relates to the molecular iodine-enriched blood of the invention, for use in therapy, especially in the treatment and/or prevention immunological diseases, inflammatory diseases, diabetes, viral and degenerative diseases, thyroiditis and optionally preeclampsia.
  • the invention relates to a method for the treatment and/or prevention of immunological diseases, inflammatory diseases, diabetes and viral and degenerative diseases, thyroiditis and optionally preeclampsia which comprises administering to a subject in need thereof a molecular iodine-enriched blood of the invention.
  • the invention relates to a method for the treatment and/or prevention of immunological diseases, inflammatory diseases, diabetes and viral and degenerative diseases, thyroiditis and optionally preeclampsia which comprises administering to a subject in need thereof a molecular iodine-enriched blood of the invention, after its purification.
  • blood tests In order to check the effectiveness of the hemotherapy of the invention and monitor the patient’s response, blood tests must be carried out at all stages; in particular, it is necessary to check the functionality of erythrocytes for oxygen transport. The shape and integrity of the membranes will be checked with the optical microscope and the experimental phase also with the SEM. Blood tests of both a donor and a patient, before purification, may be performed in vivo or ex vivo.
  • G6PD Glucose-6-Phosphate Dehydrogenase
  • G6PD Glucose-6-phosphate dehydrogenase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne l'hémothérapie, plus particulièrement un sang purifié enrichi en iode moléculaire et son utilisation dans le traitement et la prévention de plusieurs maladies, notamment du cancer. L'invention concerne également un procédé de préparation dudit sang enrichi en iode moléculaire.
PCT/IB2022/057066 2022-07-29 2022-07-29 Sang enrichi en iode moléculaire, son procédé de préparation et ses utilisations WO2024023572A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IB2022/057066 WO2024023572A1 (fr) 2022-07-29 2022-07-29 Sang enrichi en iode moléculaire, son procédé de préparation et ses utilisations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2022/057066 WO2024023572A1 (fr) 2022-07-29 2022-07-29 Sang enrichi en iode moléculaire, son procédé de préparation et ses utilisations

Publications (1)

Publication Number Publication Date
WO2024023572A1 true WO2024023572A1 (fr) 2024-02-01

Family

ID=83692845

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2022/057066 WO2024023572A1 (fr) 2022-07-29 2022-07-29 Sang enrichi en iode moléculaire, son procédé de préparation et ses utilisations

Country Status (1)

Country Link
WO (1) WO2024023572A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993004731A1 (fr) * 1991-09-03 1993-03-18 Edward Shanbrom Traitement a l'iode-iodure de cellules sanguines rouges
WO1993017693A1 (fr) * 1992-03-02 1993-09-16 Edward Shanbrom Compositions albumine-iode utilisee dans la conservation du sang, des tissus et des fluides biologiques
WO1994006289A1 (fr) * 1992-05-04 1994-03-31 Edward Shanbrom Procede d'inactivation de microbes dans le sang au moyen de l'iode

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993004731A1 (fr) * 1991-09-03 1993-03-18 Edward Shanbrom Traitement a l'iode-iodure de cellules sanguines rouges
WO1993017693A1 (fr) * 1992-03-02 1993-09-16 Edward Shanbrom Compositions albumine-iode utilisee dans la conservation du sang, des tissus et des fluides biologiques
WO1994006289A1 (fr) * 1992-05-04 1994-03-31 Edward Shanbrom Procede d'inactivation de microbes dans le sang au moyen de l'iode

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ACEVES CARMEN ET AL: "Molecular Iodine Has Extrathyroidal Effects as an Antioxidant, Differentiator, and Immunomodulator", INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, vol. 22, no. 3, 1 February 2021 (2021-02-01), Basel, CH, pages 1228, XP093024502, ISSN: 1661-6596, DOI: 10.3390/ijms22031228 *
MILLER: "Extrathyroidal Benefits of Iodine", 1 January 2006 (2006-01-01), XP093024625, Retrieved from the Internet <URL:https://www.ign.org/cm_data/2006_Miller_Extrathyroidal_Benefits_of_Iodine.pdf> [retrieved on 20230216] *
RÖSNER HARALD ET AL: "Antiproliferative/cytotoxic effects of molecular iodine, povidone-iodine and Lugol's solution in different human carcinoma cell lines", ONCOLOGY LETTERS, vol. 12, no. 3, 5 September 2016 (2016-09-05), GR, pages 2159 - 2162, XP093024605, ISSN: 1792-1074, DOI: 10.3892/ol.2016.4811 *
SOLOVYEV NIKOLAY ET AL: "Selenium and iodine in diabetes mellitus with a focus on the interplay and speciation of the elements", JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY, FISCHER, NEW YORK, NY, US, vol. 56, 20 July 2019 (2019-07-20), pages 69 - 80, XP085829722, ISSN: 0946-672X, [retrieved on 20190720], DOI: 10.1016/J.JTEMB.2019.07.005 *

Similar Documents

Publication Publication Date Title
Kılıç et al. The effects of dexmedetomidine on mesenteric arterial occlusion-associated gut ischemia and reperfusion-induced gut and kidney injury in rabbits
EP1499328B1 (fr) Methodes de traitement de l&#39;enterocolite necrosante neonatale
JP2004530659A (ja) 抗腫瘍および抗転移作用のための方法および処方
Nikitchenko et al. Anti-aging effects of antioxidant rare-earth orthovanadate nanoparticles in wistar rats
Ahmad et al. 2DG enhances the susceptibility of breast cancer cells to doxorubicin
Zhang et al. Therapeutic effect of Agaricus brasiliensis on phenylhydrazine-induced neonatal jaundice in rats
WO2024023572A1 (fr) Sang enrichi en iode moléculaire, son procédé de préparation et ses utilisations
Bocci How ozone acts and how it exerts therapeutic effects
Laurence et al. Carbogen breathing with nicotinamide improves the oxygen status of tumours in patients
Kilburn Movements of potassium during acute respiratory acidosis and recovery.
Hans et al. Effects of 1.5% glycine solution with and without 1% ethanol on the fluid balance in elderly men
Turgut et al. Effects of chronic aluminum administration on blood and liver iron-related parameters in mice
US20210315929A1 (en) Products and methods for organ protection with noble nanoparticles
CN109481459A (zh) 一种复方电解质葡萄糖注射液及其制备方法
Zima et al. Retinol and α—Tocopherol in hemodialysis patients
JP7036324B2 (ja) 抗血液凝固剤、血液凝固改善装置、血液凝固改善方法、血管内皮細胞機能改善方法及び代謝改善方法
Szwed et al. Effect of hemodialysis on oxygen-hemoglobin affinity in chronic uremics
EP2832370A1 (fr) Procédé de production de produits médicamenteux et bioactifs
RU2676761C1 (ru) Полиионный инфузионный раствор
Hamidi Comparison of Continuous and Intermittent Phototherapy in the Treatment of Toxic Neonatal Jaundice: A Double-blind Clinical Trial
Scammahorn et al. Fighting Oxidative Stress with Sulfur: Hydrogen Sulfide in the Renal and Cardiovascular Systems. Antioxidants 2021, 10, 373
CN115120580A (zh) 姜黄素在制备血红蛋白供氧效能调节剂中的应用
ES2354798T3 (es) Preparación de combinación para el tratamiento de la septicemia.
Soloveva et al. The State of Nitrogen Metabolism Under the Influence of Exogenous NO in Experimental Thermal Trauma
Viktorovich et al. The Effect of Extracorporeal Immunopharmacotherapy on Intracellular Metabolism in Cervical Cancer Patients

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22790017

Country of ref document: EP

Kind code of ref document: A1